Sugi Predict

Sugi Predict / Compounds / SCHEMBL6860177

SCHEMBL6860177

SCHEMBL6860177

O=Cc1ccc2sc3ccccc3c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR3 P46089 1/20 0.54
▸ KIF11 P52732 2/20 0.53
▸ MAPT P10636 4/20 0.45
▸ ALDH1A1 P00352 6/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ CYP2A6 P11509 3/20 0.43
▸ PTPN7 P35236 1/20 0.42
▸ DUSP3 P51452 1/20 0.42
▸ PTPN12 Q05209 1/20 0.42
▸ PTPN22 Q9Y2R2 1/20 0.42
▸ TDP1 Q9NUW8 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8720613 0.90 CYP2A6 (0.50) KIF11ALDH1A1RAB9AKDM4ECYP2A6
SCHEMBL31083678 0.90 CYP2A6 (0.50) KIF11ALDH1A1RAB9AKDM4ECYP2A6
SCHEMBL10970273 0.89 GPR3 (0.54) GPR3KIF11MAPTALDH1A1RAB9A
SCHEMBL6689810 0.87 KDM4E (0.60) GPR3KIF11MAPTALDH1A1RAB9A
SCHEMBL9537045 0.83 GPR3 (0.44) GPR3KIF11MAPTALDH1A1RAB9A
SCHEMBL13766611 0.82 GPR3 (0.56) GPR3MAPTALDH1A1RAB9AHPGD
SCHEMBL11379064 0.82 GPR3 (0.47) GPR3KIF11MAPTALDH1A1RAB9A
SCHEMBL30913876 0.81 GPR3 (0.54) GPR3MAPTALDH1A1RAB9AHPGD
SCHEMBL3056634 0.81 GPR3 (0.54) GPR3MAPTALDH1A1RAB9AHPGD
SCHEMBL13242812 0.79 APP (0.41) KIF11MAPTALDH1A1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119978006-A Preparation of host-guest doped TADF nano-particles and application of host-guest doped TADF nano-particles in STED imaging 中国农业大学 2025-05-13 — — CN claimed
EP-4353231-A1 COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-ASSOCIATED GASTROINTESTINAL SIDE EFFECTS OnQuality Pharmaceuticals China Ltd. (CN) 2024-04-17 — — EP claimed
CN-114957204-A Bistyryl derivative-based low-threshold organic solid-state laser and high-efficiency organic light-emitting field-effect transistor 首都师范大学 2022-08-30 — — CN claimed
EP-3191098-A1 COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS G1 Therapeutics, Inc. (US) 2017-07-19 — — EP claimed
EP-2831080-B1 LACTAM KINASE INHIBITORS TAVARES FRANCIS XAVIER (US) 2017-03-15 — — EP claimed
US-20160310499-A1 Highly Active Anti-Neoplastic and Anti-Proliferative Agents G1 THERAPEUTICS, INC. 2016-10-27 — — US claimed
WO-2016040858-A1 COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS G1 THERAPEUTICS, INC. (US) 2016-03-17 — — WO claimed
US-9260442-B2 Lactam kinase inhibitors G1 THERAPEUTICS, INC. (US) 2016-02-16 — — US claimed
EP-2955183-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2015-12-16 — — EP claimed
US-20150297606-A1 Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation G1 THERAPEUTICS, INC. (US) 2015-10-22 — — US claimed
US-20140271466-A1 HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation G1 THERAPEUTICS, INC. (US) 2014-09-18 — — US claimed
US-20140275067-A1 Transient Protection of Normal Cells During Chemotherapy G1 THERAPEUTICS, INC. (US) 2014-09-18 — — US claimed
US-8829012-B2 CDK inhibitors G1 THERAPEUTICS, INC. (US) 2014-09-09 — — US claimed
US-8822683-B2 CDK inhibitors G1 THERAPEUTICS, INC. (US) 2014-09-02 — — US claimed
US-20140142306-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2014-05-22 — — US claimed
US-20140142299-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2014-05-22 — — US claimed
US-8691830-B2 CDK inhibitors G1 THERAPEUTICS, INC. (US) 2014-04-08 — — US claimed
US-8598197-B2 CDK inhibitors G1 THERAPEUTICS, INC. (US) 2013-12-03 — — US claimed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US claimed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 GPR3 3134/4885KIF11 614/4885MAPT 2057/4885
US-20140275067-A1 Transient Protection of Normal Cells During Chemotherapy CDK6, CCNC, MCL1 GPR3 4447/4885KIF11 2894/4885MAPT 4062/4885
US-20140142306-A1 CDK Inhibitors CDK3, CDK9, CDK6 GPR3 3134/4885KIF11 614/4885MAPT 2057/4885
US-20140271466-A1 HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation RB1, CDK4, CDKN1A GPR3 3071/4885KIF11 1648/4885MAPT 2961/4885
US-20150297606-A1 Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation CTSA, MCL1, ERCC1 GPR3 3757/4885KIF11 4520/4885MAPT 3519/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 GPR3 3134/4885KIF11 614/4885MAPT 2057/4885
US-20140142299-A1 CDK Inhibitors CDK3, CDK9, CDK6 GPR3 3134/4885KIF11 614/4885MAPT 2057/4885
US-20160310499-A1 Highly Active Anti-Neoplastic and Anti-Proliferative Agents MKI67, PCNA, HRAS GPR3 4730/4885KIF11 2499/4885MAPT 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.